DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management ...
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern ...
EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence ...
Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy. Curatio Advisors starts its ...
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a ...
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase ...
Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical ...
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit. Executive Order 14273, signed April 15, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results